Данная версия сайта не обновляется с 10.09.2018, смотрите новую версию
 

Current issue #15, 2018

03.05.2018

Pharmacists asked not to be penalized for drug dispensing regulations violation until e-prescriptions are implemented

Pharmacists at Russia’s regional pharmacies state that they are ready to make Rx drug prescriptions themselves as they believe that doctors do not have either relevant knowledge or time to do that. Patients keep handing over paper sheets with drugs assigned in scrawled handwriting. Pharmacists know that they may be penalized for selling pharmaceuticals based on such prescriptions, but they would often run out of words trying to explain that to customers. Therefore, pharmacies propose taking receipts from customers and consider them prescriptions of a kind.

[PharmVestnik # 15, 02/05/2018, p. 1, cont’d p. 4]

// Pharma Retailing – FMCG Relationships

National Chamber for Pharmaceuticals drafts an appeal to President of Russia on inadmissibility of selling drugs at stores

According to experts, the Russian pharmacy market faces hard times pressed both by government actions (e.g., the initiative on legalization of drug sales through FMCG channels) and progressively harder relationships with manufacturers and distributors. Despite the latter fact, the competition in the sector remains tough, with the number of the points of sales growing. Under the circumstances, the pharma community decided to appeal to the President of Russia. At the same time, it is rumored that Vice-Premier Igor Shuvalov primarily pushing legalization of drug sales at stores may quit soon. Then the issue will be likely to resolve on its own.

[PharmVestnik # 15, 02/05/2018, p. 2]

// Health Insurance

Health insurers happy about their status quo

The discussion on the role of health insurance companies in the Mandatory Health Insurance (MHI) system is nothing new. In late March, Valentina Matvienko, the spokeswoman of the Federation Council, challenged the efficacy of the current MHI system and the need for health insurers operating within this system. The insurers made a clever move and turned directly to patients. By coincidence, it was then that the All-Russia Public Opinion Research Center initiated a survey focused on insurance companies. The public opinion poll results have proved to be quite satisfactory for the insurers.

[PharmVestnik # 15, 02/05/2018, p. 6]

// Pharma Distribution

Pharmacy reputation no longer reflects its financial stability

Distributors are shifting gears in their relationships with pharmacies. Experts state that even the pharmacy chains that have recently set the example for the entire market are not immune to smashup. Therefore, a bank guarantee becomes a principal agreement for shipment.

[PharmVestnik # 15, 02/05/2018, p. 6]

// Health Strategies & Programs

Experts presented scenarios for pharma strategic development

Kaluga was the venue of the 4th Annual International Forum ‘Pharmelovution-2018’ hosted by the Vedomosti newspaper jointly with Kaluga Region government, Agency for Innovative Development — Center for Cluster Development of Kaluga Region, and Kaluga Pharmaceutical Cluster. The plenary session focused on short- and long-term prospects of the Russian healthcare system development and the pharmaceutical industry development, in particular.

[PharmVestnik # 15, 02/05/2018, p. 7]

// Drug Labeling

Tracking a drug package will cost manufacturer 50 kopecks

At drug labeling presentations throughout 2017, Federal Service for Surveillance in Healthcare and Social Development officials would often state that tracking every drug package from the manufacturer to the end consumer would rule out counterfeit products. Pharma manufacturers participating in the labeling pilot project would add that at last they would be able to stop paying distributors for the product sales data as they would be able to receive such reports generated directly by the information system. The market players would occasionally come up with questions about the cost of such information, but these questions have been somewhere in the background mainly concerning third-party users. Last year, a much hotter topic was the mandatory labeling implementation deadline. Now, it is time to speak about the costs.

[PharmVestnik # 15, 02/05/2018, p. 8]

// Disease Management

Cancer care will not be able to do without co-funding

In Russia, nearly 50% of cancer cases are diagnosed at early stages, this parameter gradually growing together with the morbidity rate. However, treatment access does not improve; therefore, the prospects of positive outcomes are dim. This vicious circle may be done away with only if there is a viable malignant neoplasm control program based on best medical technologies.

[PharmVestnik # 15, 02/05/2018, p. 11]

// Import Substitution

Is the situation with medical product manufacturing in Russia as bad as perceived by State Duma?

On April 20, after discussing with business and expert circles the bill on counter-moves to respond to the US sanctions, State Duma Chairman Vyacheslav Volodin stated that the Ministry of Health (MoH) had failed the imported drug substitution. This statement was rather strange not only because the spokesperson had mixed up the MoH and the Ministry of Industry and Trade but also in the light of official data on the implementation of the Pharma-2020 Program.

[PharmVestnik # 15, 02/05/2018, p. 13]

// Insight – Imports

API imports to Russia, 2017

According to RNC Pharma, in 2017, imports of active pharmaceutical ingredients (API) to Russia set a historic record both in value (73.9B RUB in release into free circulation prices) and real terms (12.3 thsd tons). The import growth dynamics was also high at more than +22% in rubles and about 5% in real terms.

[PharmVestnik # 15, 02/05/2018, pp. 20-21]

// Insight – Pharmaceuticals

Government trastuzumab supply contracts, 2016—2017: a review

This analysis is made by PharmVestnik analysts based on Zakupki (Procurement) data analytics platform. Most likely, not elsewhere drug import substitution is as important as in cancer treatment, the more so as recently, a number of drugs that significantly boost the treatment efficacy vs. the standard of care (chemotherapy) have been launched to the market. All that is left to do is to improve access to these innovative drugs.

[PharmVestnik # 15, 02/05/2018, p. 22]

// Insight – Pharmaceuticals

Anticoagulants market, 2015—2017: a review

This analysis is made by PharmVestnik analysts based on AlphaRM data. Increasingly often, experts focus on low, sometimes negative, sales dynamics of certain drug groups, especially in real terms. They usually look for the root causes in the erosion of the population’s purchasing power in cases of out-ot-pocket purchases and in declining state funding in case of government procurement. Purely financial causes of the market decline are on the surface. But are there ‘silent’ factors driving the demand for specific drug groups up and down?

[PharmVestnik # 15, 02/05/2018, p. 23]

// Pharma Manufacturing

Radiopharmaceutical manufacturing for Sverdlovsk Region to be localized at the Ural State University

A cancer diagnostics center will be set up at the Ural State University. It will be based on own isotope and radiopharmaceutical manufacturing at the Nuclear Medicine Cyclotron Center. The minister of health of Sverdlovsk Region has supported the idea.

[PharmVestnik # 15, 02/05/2018, p. 25]

Регистрация скоро будет доступна на новой версии сайта.